Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

详细信息	查看全文 | 推荐本文 |

• 作者：Prof Winette TA van der Graaf ; MD^a ; ^{w.vandergraaf@onco.umcn.nl} ; Prof Jean-Yves Blay ; MD^b ; Sant P Chawla ; MD^c ; Dong-Wan Kim ; MD^d ; Binh Bui-Nguyen ; MD^e ; Paolo G Casali ; MD^f ; Prof Patrick Sch&ouml ; ffski ; MD^g ; Massimo Aglietta ; MD^h ; Arthur P Staddon ; MDⁱ ; Yasuo Beppu ; MD^j ; Axel Le Cesne ; MD^k ; Prof Hans Gelderblom ; MD^l ; Prof Ian R Judson ; MD^m ; Nobuhito Araki ; MDⁿ ; Monia Ouali ; MSc^o ; Sandrine Marreaud ; MD^o ; Rachel Hodge ; MSc^p ; Mohammed R Dewji ; MSc^p ; Corneel Coens ; MSc^o ; George D Demetri ; MD^q ; Prof Christopher D Fletcher ; MD^r ; Angelo Paolo Dei Tos ; MD^s ; Prof Peter Hohenberger ; MD^t ; on behalf of the EORTC Soft Tissue ; Bone Sarcoma Group ; the PALETTE study group
• 刊名：The Lancet
• 出版年：2012
• 期刊代码：182_01406736
• 类别：med
• 出版时间：19-25 May, 2012
• 卷：379
• 期：9829
• 页码：1879-1886
• 文件大小：291 K

摘要

| Figures/TablesFigures/Tables | ReferencesReferencesl version="1.0" encoding="UTF-8"?>

lass="h3">Summary

lass="h4">Background

Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.

lass="h4">Methods

This phase 3 study was done in 72 institutions, across 13 countries. Patients with angiogenesis inhibitor-naive, metastatic soft-tissue sarcoma, progressing despite previous standard chemotherapy, were randomly assigned by an interactive voice randomisation system in a 2:1 ratio in permuted blocks (with block sizes of six) to receive either pazopanib 800 mg once daily or placebo, with no subsequent cross-over. Patients, investigators who gave the treatment, those assessing outcomes, and those who did the analysis were masked to the allocation. The primary endpoint was progression-free survival. Efficacy analysis was by intention to treat. The trial is registered with , number .

lass="h4">Findings

372 patients were registered and 369 were randomly assigned to receive pazopanib (n=246) or placebo (n=123). Median progression-free survival was 4路6 months (95%CI 3路7-4路8) for pazopanib compared with 1路6 months (0路9-1路8) for placebo (hazard ratio [HR] 0路31, 95%CI 0路24-0路40; p<0路0001). Overall survival was 12路5 months (10路6-14路8) with pazopanib versus 10路7 months (8路7-12路8) with placebo (HR 0路86, 0路67-1路11; p=0路25). The most common adverse events were fatigue (60 in the placebo group [49%] vs 155 in the pazopanib group [65%]), diarrhoea (20 [16%] vs 138 [58%]), nausea (34 [28%] vs 129 [54%]), weight loss (25 [20%] vs 115 [48%]), and hypertension (8 [7%] vs 99 [41%]). The median relative dose intensity was 100%for placebo and 96%for pazopanib.

lass="h4">Interpretation

Pazopanib is a new treatment option for patients with metastatic non-adipocytic soft-tissue sarcoma after previous chemotherapy.

lass="h4">Funding

GlaxoSmithKline.